{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:15:18Z","timestamp":1791825318923,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100012128","name":"Austin Medical Research Foundation","doi-asserted-by":"crossref","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100012128","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1073378"],"award-info":[{"award-number":["1073378"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1923526"],"award-info":[{"award-number":["1923526"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian Society for Antimicrobials","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3011-2","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T11:43:28Z","timestamp":1520250208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Morbidity from in-hospital complications is greater than treatment failure in patients with Staphylococcus aureus bacteraemia"],"prefix":"10.1186","volume":"18","author":[{"name":"VANESSA study group, on behalf of the Australasian Society for Infectious Diseases (ASID) Clinical Research Network (CRN)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha E.","family":"Holmes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Owen","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan J.","family":"van Hal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy J.","family":"Munckhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Athan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony M.","family":"Korman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen C.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Turnidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D. R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P.","family":"Howden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,5]]},"reference":[{"issue":"3","key":"3011_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/infdis\/jir270","volume":"204","author":"NE Holmes","year":"2011","unstructured":"Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis. 2011;204(3):340\u20137.","journal-title":"J Infect Dis"},{"issue":"2","key":"3011_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/CMR.05022-11","volume":"25","author":"SJ van Hal","year":"2012","unstructured":"van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev. 2012;25(2):362\u201386.","journal-title":"Clin Microbiol Rev"},{"issue":"11","key":"3011_CR3","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1086\/375057","volume":"36","author":"TP Lodise","year":"2003","unstructured":"Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis. 2003;36(11):1418\u201323.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"3011_CR4","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1086\/502156","volume":"24","author":"O Lesens","year":"2003","unstructured":"Lesens O, Methlin C, Hansmann Y, et al. Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity. Infect Control Hosp Epidemiol. 2003;24(12):890\u20136.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"10","key":"3011_CR5","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med. 1985;13(10):818\u201329.","journal-title":"Crit Care Med"},{"issue":"7","key":"3011_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707\u201310.","journal-title":"Intensive Care Med"},{"issue":"1","key":"3011_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.7326\/0003-4819-140-1-200401060-00008","volume":"140","author":"DL Paterson","year":"2004","unstructured":"Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med. 2004;140(1):26\u201332.","journal-title":"Ann Intern Med"},{"issue":"4","key":"3011_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1086\/313753","volume":"30","author":"JS Li","year":"2000","unstructured":"Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633\u20138.","journal-title":"Clin Infect Dis"},{"key":"3011_CR9","unstructured":"The Australian and New Zealand Intensive Care Society. CORE - Data collection tools. Available at: http:\/\/www.anzics.com.au\/Pages\/CORE\/data-tools.aspx . Accessed 26 Feb 2018."},{"issue":"4","key":"3011_CR10","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1128\/AAC.01602-07","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52(4):1330\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3011_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/jac\/dkn080","volume":"62","author":"PR Ingram","year":"2008","unstructured":"Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2008;62(1):168\u201371.","journal-title":"J Antimicrob Chemother"},{"key":"3011_CR12","unstructured":"Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard-Seventh Edition. CLSI document M07-A7. Wayne, Philadelphia, USA: CLSI, 2006."},{"key":"3011_CR13","volume-title":"National Statement on Ethical Conduct in Human Research","author":"National Health and Medical Research Council","year":"2007","unstructured":"National Health and Medical Research Council. National Statement on Ethical Conduct in Human Research. Canberra: Australian Government; 2007."},{"key":"3011_CR14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jinf.2013.10.015","volume":"68","author":"AJ Kaasch","year":"2014","unstructured":"Kaasch AJ, Barlow G, Edgeworth JD, et al. Staphylococcus aureus bloodstream infection: A pooled analysis of five prospective, observational studies. J Infect. 2014;68:242\u201351.","journal-title":"J Infect"},{"issue":"4","key":"3011_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/jtm.12133","volume":"21","author":"YP Zhou","year":"2014","unstructured":"Zhou YP, Wilder-Smith A, Hsu LY. The role of international travel in the spread of methicillin-resistant Staphylococcus aureus. J Travel Med. 2014;21(4):272\u201381.","journal-title":"J Travel Med"},{"issue":"5","key":"3011_CR16","doi-asserted-by":"publisher","first-page":"e63716","DOI":"10.1371\/journal.pone.0063716","volume":"8","author":"K Olsen","year":"2013","unstructured":"Olsen K, Danielsen K, Wilsgaard T, et al. Obesity and Staphylococcus aureus nasal colonization among women and men in a general population. PLoS One. 2013;8(5):e63716.","journal-title":"PLoS One"},{"issue":"9","key":"3011_CR17","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/pds.3461","volume":"22","author":"C Longo","year":"2013","unstructured":"Longo C, Bartlett G, Macgibbon B, et al. The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf. 2013;22(9):970\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3011_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2334-7-13","volume":"7","author":"R Huttunen","year":"2007","unstructured":"Huttunen R, Laine J, Lumio J, Vuento R, Syrjanen J. Obesity and smoking are factors associated with poor prognosis in patients with bacteraemia. BMC Infect Dis. 2007;7:13.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"3011_CR19","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.01568-12","volume":"57","author":"SJ van Hal","year":"2013","unstructured":"van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57(2):734\u201344.","journal-title":"Antimicrob Agents Chemother"},{"key":"3011_CR20","doi-asserted-by":"crossref","unstructured":"Norton K, Ingram PR, Heath CH, Manning L. Risk factors for nephrotoxicity in patients receiving outpatient continuous infusions of vancomycin in an Australian tertiary hospital. J Antimicrob Chemother. 2014;69(3):805\u20138.","DOI":"10.1093\/jac\/dkt402"},{"issue":"2","key":"3011_CR21","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.amjmed.2009.05.031","volume":"123","author":"KA Hazlewood","year":"2010","unstructured":"Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination? Am J Med. 2010;123(2):182. e1-.e7","journal-title":"Am J Med"},{"key":"3011_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1201\/b13787-8","volume-title":"Kucers' The Use of Antibiotics","author":"J Turnidge","year":"2010","unstructured":"Turnidge J. Isoxazolyl penicillins: oxacillin, cloxacillin, dicloxacillin and flucloxacillin. In: Grayson ML, editor. Kucers' The Use of Antibiotics. 6th ed. London: Hodder Arnold; 2010. p. 100\u201314.","edition":"6"},{"issue":"12","key":"3011_CR23","first-page":"1009","volume":"37","author":"B Xu","year":"2008","unstructured":"Xu B, Murray M. Flucloxacillin induced acute renal failure. Aust Fam Physician. 2008;37(12):1009\u201311.","journal-title":"Aust Fam Physician"},{"issue":"7-8","key":"3011_CR24","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1177\/106002809202600724","volume":"26","author":"MR Lestico","year":"1992","unstructured":"Lestico MR, Vick KE, Hetsko CM. Hepatic and renal dysfunction following nafcillin administration. Ann Pharmacother. 1992;26(7-8):985\u201390.","journal-title":"Ann Pharmacother"},{"issue":"10","key":"3011_CR25","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/ajhp\/54.10.1176","volume":"54","author":"AF Dahlgren","year":"1997","unstructured":"Dahlgren AF. Adverse drug reactions in home care patients receiving nafcillin or oxacillin. Am J Health Syst Pharm. 1997;54(10):1176\u20139.","journal-title":"Am J Health Syst Pharm"},{"issue":"11","key":"3011_CR26","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1128\/AAC.00485-11","volume":"55","author":"S Lee","year":"2011","unstructured":"Lee S, Choe PG, Song KH, et al. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia? Antimicrob Agents Chemother. 2011;55(11):5122\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"3011_CR27","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1128\/AAC.02800-14","volume":"58","author":"J Li","year":"2014","unstructured":"Li J, Echevarria KL, Hughes DW, Cadena JA, Bowling JE, Lewis JS 2nd. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2014;58(9):5117\u201324.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"3011_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/cid\/ciu301","volume":"59","author":"I Youngster","year":"2014","unstructured":"Youngster I, Shenoy ES, Hooper DC, Nelson SB. Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting. Clin Infect Dis. 2014;59(3):369\u201375.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"3011_CR29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40121-017-0148-z","volume":"6","author":"LK Flynt","year":"2017","unstructured":"Flynt LK, Kenney RM, Zervos MJ, Davis SL. The Safety and Economic Impact of Cefazolin versus Nafcillin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections. Infect Dis Ther. 2017;6(2):225\u201331.","journal-title":"Infect Dis Ther"},{"issue":"2","key":"3011_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/01.CCM.0B013E3181611F914","volume":"36","author":"AL Crowley","year":"2008","unstructured":"Crowley AL, Peterson GE, Benjamin DK Jr, et al. Venous thrombosis in patients with short- and long-term central venous catheter-associated Staphylococcus aureus bacteremia. Crit Care Med. 2008;36(2):385\u201390.","journal-title":"Crit Care Med"},{"issue":"3","key":"3011_CR31","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.thromres.2012.06.013","volume":"130","author":"E Martin","year":"2012","unstructured":"Martin E, Cevik C, Nugent K. The role of hypervirulent Staphylococcus aureus infections in the development of deep vein thrombosis. Thromb Res. 2012;130(3):302\u20138.","journal-title":"Thromb Res"},{"issue":"7","key":"3011_CR32","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5694\/j.1326-5377.2009.tb02841.x","volume":"191","author":"JD Turnidge","year":"2009","unstructured":"Turnidge JD, Kotsanas D, Munckhof W, et al. Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust. 2009;191(7):368\u201373.","journal-title":"Med J Aust"},{"issue":"1","key":"3011_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/1471-2334-12-249","volume":"12","author":"SY Tong","year":"2012","unstructured":"Tong SY, van Hal SJ, Einsiedel L, Currie BJ, Turnidge JD. Impact of ethnicity and socio-economic status on Staphylococcus aureus bacteremia incidence and mortality: a heavy burden in indigenous Australians. BMC Infect Dis. 2012;12(1):249.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"3011_CR34","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1086\/527389","volume":"46","author":"JL Wang","year":"2008","unstructured":"Wang JL, Chen SY, Wang JT, et al. Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus. Clin Infect Dis. 2008;46(6):799\u2013806.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"3011_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jhin.2011.03.010","volume":"78","author":"E Forsblom","year":"2011","unstructured":"Forsblom E, Ruotsalainen E, Molkanen T, Ollgren J, Lyytikainen O, Jarvinen A. Predisposing factors, disease progression and outcome in 430 prospectively followed patients of healthcare- and community-associated Staphylococcus aureus bacteraemia. J Hosp Infect. 2011;78(2):102\u20137.","journal-title":"J Hosp Infect"},{"issue":"4","key":"3011_CR36","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1469-0691.2010.03265.x","volume":"17","author":"H Asgeirsson","year":"2011","unstructured":"Asgeirsson H, Gudlaugsson O, Kristinsson KG, Heiddal S, Kristjansson M. Staphylococcus aureus bacteraemia in Iceland, 1995-2008: changing incidence and mortality. Clin Microbiol Infect. 2011;17(4):513\u20138.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"3011_CR37","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/cid\/cit499","volume":"57","author":"LE Lopez-Cortes","year":"2013","unstructured":"Lopez-Cortes LE, Del Toro MD, Galvez-Acebal J, et al. Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia. Clin Infect Dis. 2013;57(9):1225\u201333.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"3011_CR38","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/cid\/cir935","volume":"54","author":"SJ van Hal","year":"2012","unstructured":"van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755\u201371.","journal-title":"Clin Infect Dis"},{"issue":"13","key":"3011_CR39","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jama.2014.2637","volume":"311","author":"KM Kaukonen","year":"2014","unstructured":"Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014;311(13):1308\u201316.","journal-title":"JAMA"},{"issue":"4","key":"3011_CR40","doi-asserted-by":"crossref","first-page":"E309","DOI":"10.33321\/cdi.2014.38.51","volume":"38","author":"GW Coombs","year":"2014","unstructured":"Coombs GW, Nimmo GR, Daly DA, et al. Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2013. Commun Dis Intell Q Rep. 2014;38(4):E309\u201319.","journal-title":"Commun Dis Intell Q Rep"},{"issue":"4","key":"3011_CR41","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jinf.2016.07.005","volume":"73","author":"N Gotland","year":"2016","unstructured":"Gotland N, Uhre ML, Mejer N, et al. Long-term mortality and causes of death associated with Staphylococcus aureus bacteremia. A matched cohort study. J Infect. 2016;73(4):346\u201357.","journal-title":"J Infect"},{"issue":"5","key":"3011_CR42","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10096-016-2598-8","volume":"35","author":"D Yahav","year":"2016","unstructured":"Yahav D, Yassin S, Shaked H, et al. Risk factors for long-term mortality of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2016;35(5):785\u201390.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"3011_CR43","doi-asserted-by":"crossref","unstructured":"Asgeirsson H, Thalme A, Weiland O. Staphylococcus aureus bacteraemia and endocarditis - epidemiology and outcome: a review. Infect Dis (Lond). 2017:1\u201318.","DOI":"10.1080\/23744235.2017.1392039"},{"issue":"6","key":"3011_CR44","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3201\/eid\/1706.101037","volume":"17","author":"JM Aguado","year":"2011","unstructured":"Aguado JM, San Juan R, Lalueza A, et al. High vancomycin MIC and complicated methicillin-susceptible Staphylococcus aureus bacteraemia. Emerg Infect Dis. 2011;17(6):1099\u2013102.","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"3011_CR45","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3201\/eid2206.151709","volume":"22","author":"R San-Juan","year":"2016","unstructured":"San-Juan R, Viedma E, Chaves F, et al. High MICs for vancomycin and daptomycin and complicated catheter-related bloodstream infections with methicillin-sensitive Staphylococcus aureus. Emerg Infect Dis. 2016;22(6):1057\u201366.","journal-title":"Emerg Infect Dis"},{"key":"3011_CR46","doi-asserted-by":"crossref","unstructured":"Sullivan SB, Austin ED, Stump S, et al. Reduced vancomycin susceptibility of methicillin-susceptible Staphylococcus aureus has no significant impact on mortality but results in an increase in complicated infection. Antimicrob Agents Chemother. 2017;61(7):e00316-17.","DOI":"10.1128\/AAC.00316-17"},{"issue":"15","key":"3011_CR47","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1001\/jama.2014.6364","volume":"312","author":"AC Kalil","year":"2014","unstructured":"Kalil AC, Van Schooenveld TC, Fey PD, Rupp ME. Association between vancomycin minimum inhibitory concentration and mortality among patients with Staphylococcus aureus bloodstream infections: a systematic review and meta-analysis. JAMA. 2014;312(15):1552\u201364.","journal-title":"JAMA"},{"issue":"9","key":"3011_CR48","doi-asserted-by":"publisher","first-page":"5276","DOI":"10.1128\/AAC.00658-16","volume":"60","author":"SM Baxi","year":"2016","unstructured":"Baxi SM, Clemenzi-Allen A, Gahbauer A, et al. Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2016;60(9):5276\u201384.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"3011_CR49","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18\u201355.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3011_CR50","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jinf.2016.12.007","volume":"74","author":"NJ Hos","year":"2017","unstructured":"Hos NJ, Jazmati N, Stefanik D, et al. Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials. J Infect. 2017;74(3):248\u201359.","journal-title":"J Infect"},{"key":"3011_CR51","doi-asserted-by":"crossref","unstructured":"Song KH, Kim M, Kim CJ, et al. Impact of vancomycin MIC on treatment outcomes in invasive Staphylococcus aureus infections. Antimicrob Agents Chemother. 2017;61(3):e01845-16.","DOI":"10.1128\/AAC.01845-16"},{"issue":"4","key":"3011_CR52","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.1469-0691.2010.03284.x","volume":"17","author":"KO Gradel","year":"2011","unstructured":"Gradel KO, Thomsen RW, Lundbye-Christensen S, Nielsen H, Schonheyder HC. Baseline C-reactive protein level as a predictor of mortality in bacteraemia patients: a population-based cohort study. Clin Microbiol Infect. 2011;17(4):627\u201332.","journal-title":"Clin Microbiol Infect"},{"key":"3011_CR53","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/1471-2334-13-182","volume":"13","author":"JT Wang","year":"2013","unstructured":"Wang JT, Wu HS, Weng CM, Hsu LY, Wang FD. Prognosis of patients with methicillin-resistant Staphylococcus aureus bloodstream infection treated with teicoplanin: a retrospective cohort study investigating effect of teicoplanin minimum inhibitory concentrations. BMC Infect Dis. 2013;13:182.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"3011_CR54","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10096-006-0096-0","volume":"25","author":"R Khatib","year":"2006","unstructured":"Khatib R, Saeed S, Sharma M, Riederer K, Fakih MG, Johnson LB. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2006;25(3):181\u20135.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12","key":"3011_CR55","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1093\/jac\/dkq373","volume":"65","author":"M Paul","year":"2010","unstructured":"Paul M, Kariv G, Goldberg E, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2010;65(12):2658\u201365.","journal-title":"J Antimicrob Chemother"},{"key":"3011_CR56","doi-asserted-by":"crossref","unstructured":"Kaasch AJ, Rieg S, Kuetscher J, et al. Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study. Infection. 2013;41(5):979\u201385.","DOI":"10.1007\/s15010-013-0428-9"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3011-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T10:11:00Z","timestamp":1751451060000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3011-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,5]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3011"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3011-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,5]]},"assertion":[{"value":"19 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The following are members of the steering committee for the VANESSA (VANcomycin Efficacy in Staphylococcal Sepsis in Australasia) study: Natasha E. Holmes (Austin Health), Paul D. R. Johnson (Austin Health), Benjamin P. Howden (Austin Health), John D. Turnidge (Women\u2019s and Children\u2019s Hospital), J. Owen Robinson (Royal Perth Hospital), Sebastian J. van Hal (Liverpool Hospital, Royal Prince Alfred Hospital), Wendy J. Munckhof (Princess Alexandra Hospital), Eugene Athan (Barwon Health), Tony M. Korman (Monash Health), Allen C. Cheng (Alfred Hospital).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"Human research ethics committee approval was obtained at each of the participating sites (Austin Health H2010\/04092, Alfred Hospital 392\/10, Barwon Health 10\/141, Liverpool Hospital HREC\/10\/LPOOL\/189, Monash Health 10340A, Princess Alexandra Hospital HREC\/10\/QPAH\/296, Royal Prince Alfred Hospital HREC\/12\/RPAH\/290, Royal Perth Hospital 2011\/021). Written informed consent was obtained from all participants at all participating sites.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"107"}}